Small Molecules

24 April 2025

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

23 April 2025

Parabilis Medicines to Present First Preclinical Data on ERG Degrader Program at AACR Annual Meeting

23 April 2025

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

23 April 2025

Ensem Therapeutics Announces U.S. FDA IND Clearance to Initiate Clinical Development of ETX-636

23 April 2025

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

17 April 2025

Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial

17 April 2025

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 – a Novel IRAK4 Degrader for Inflammatory Conditions

17 April 2025

Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149

16 April 2025

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

15 April 2025

Evommune Initiates Phase 2b Trial of MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Chronic Spontaneous Urticaria

15 April 2025

Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Novel KIF18A Inhibitor ATX-295 and Receives FDA Fast Track Designation for Lead Assets ATX-295 and DHX9 Inhibitor ATX-559

15 April 2025

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron

15 April 2025

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

10 April 2025

LifeMine Announces First Participant Dosed in First-in-human Phase 1 Clinical Trial of LIFE-001, Designed De Novo to Become a Field Dominating Immunosuppressive for Immune-mediated Disorders and Transplantation

5 April 2025

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

4 April 2025

Auron Presents New Preclinical Data for AUTX-703 in Small Cell Lung Cancer (SCLC)

4 April 2025

Pretzel Therapeutics Initiates Phase 1 Clinical Study Evaluating PX578, Lead Therapeutic in its Bioenergetics Restoration Franchise

4 April 2025

Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors

3 April 2025

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

2 April 2025

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

2 April 2025

Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma

2 April 2025

BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors

1 April 2025

Merck Exercised the Option for the Global Rights of Abbisko Therapeutics’s Pimicotinib

31 March 2025

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

31 March 2025

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

28 March 2025

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

26 March 2025

AnHorn Medicines Announces First Subject Dosed in AH-001 Phase I Clinical Trial in the United States

26 March 2025

Blacksmith Medicines Presents the Discovery and Chemical Structure of FG-2101, a Novel Antibiotic Candidate Targeting LpxC, at the American Chemical Society (ACS) National Meeting

26 March 2025

Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older

26 March 2025

Kelun-Biotech’s Radionuclide-Drug Conjugate (RDC) SKB107 Receives NMPA Approval For The Treatment of Bone Metastases in Solid Tumors

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

Report Package: Bispecific Antibodies

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

CD73 Inhibitor Pipeline Review

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis